dailypolitical.com
Positivewww.dailypolitical.com ·
vanguard group inc acquires 607669 shares of trevi therapeutics inc trvi
TAX_ECON_PRICEECON_STOCKMARKETWB_1331_HEALTH_TECHNOLOGIESWB_2453_ORGANIZED_CRIME
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article reports institutional shareholding changes in Trevi Therapeutics, a biotech firm focused on non-opioid pain therapies. No direct commercial mechanism (e.g., product launch, trial results, supply chain event) is described. The impact is limited to equity positioning and sentiment, not operational business lines or commodity/input prices. Weak commercial mechanism; no concrete revenue/cost/margin channel identified.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Vanguard Group increased its stake in Trevi Therapeutics by 10.4%, acquiring 607,669 shares in Q4.
- Total Vanguard holdings in Trevi Therapeutics: 6,434,655 shares valued at ~$80.56 million.
- NBC Securities increased its stake by 750%, Zurcher Kantonalbank by 85.4%.
- Trevi Therapeutics reported a quarterly loss of $0.09 per share, missing estimates.
- Stock opened at $15.27, market cap $2.17 billion, 52-week range $5.38-$16.12.